Protagonist Therapeutics (PTGX) News Today $41.11 +0.07 (+0.17%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Janney Montgomery Scott LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Janney Montgomery Scott LLC purchased a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,249 shares of the companNovember 17 at 3:02 AM | marketbeat.comAmalgamated Bank Buys 15,301 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Amalgamated Bank increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 756.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,324 shares of the company's stock after purchasiNovember 16 at 3:19 AM | marketbeat.comWhat is HC Wainwright's Estimate for PTGX FY2024 Earnings?November 16 at 2:55 AM | americanbankingnews.comFY2024 Earnings Forecast for PTGX Issued By HC WainwrightProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Stock analysts at HC Wainwright raised their FY2024 EPS estimates for Protagonist Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $1.82 per share foNovember 14 at 8:35 AM | marketbeat.comQ4 EPS Estimate for Protagonist Therapeutics Cut by AnalystProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Analysts at HC Wainwright lowered their Q4 2025 EPS estimates for shares of Protagonist Therapeutics in a report released on Monday, November 11th. HC Wainwright analyst D. Tsao now expects that the company will earn $0.87 per share forNovember 13, 2024 | marketbeat.comProtagonist Therapeutics (PTGX) Receives a Buy from Truist FinancialNovember 13, 2024 | markets.businessinsider.comBullish Outlook on Protagonist Therapeutics Amid Promising JNJ-2113 Phase 3 Trial PotentialNovember 11, 2024 | markets.businessinsider.comProtagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Catalysts and Strategic CollaborationsNovember 11, 2024 | markets.businessinsider.comProtagonist Therapeutics (NASDAQ:PTGX) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Protagonist Therapeutics in a research note on Monday.November 11, 2024 | marketbeat.comNew York State Teachers Retirement System Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)New York State Teachers Retirement System bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 24,592 shares of the company's stock, valued at appNovember 10, 2024 | marketbeat.comPromising Potential and Strong Financial Position Justify Buy Rating for Protagonist TherapeuticsNovember 9, 2024 | markets.businessinsider.comProtagonist Therapeutics (PTGX) Gets a Buy from J.P. MorganNovember 9, 2024 | markets.businessinsider.comProtagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High - Here's What HappenedProtagonist Therapeutics (NASDAQ:PTGX) Sets New 1-Year High - Should You Buy?November 8, 2024 | marketbeat.comPositive Outlook and Buy Rating for Protagonist Therapeutics Based on Promising Phase III Results and Strategic PositioningNovember 8, 2024 | markets.businessinsider.comWedbush Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform RecommendationNovember 7, 2024 | msn.com41,818 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Financial Enhancement Group LLCFinancial Enhancement Group LLC acquired a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,8November 7, 2024 | marketbeat.comWhat is Wedbush's Forecast for PTGX Q3 Earnings?Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Investment analysts at Wedbush issued their Q3 2024 earnings estimates for Protagonist Therapeutics in a research report issued to clients and investors on Monday, November 4th. Wedbush analyst Y. Zhong forecasts that the company will eNovember 7, 2024 | marketbeat.comProtagonist Therapeutics Share Price (PTGX.US)November 5, 2024 | lse.co.ukProtagonist Therapeutics initiated with an Outperform at WedbushNovember 5, 2024 | markets.businessinsider.comWedbush starts Protagonist Therapeutics with an Outperform, $58 targetNovember 5, 2024 | markets.businessinsider.comProtagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.4% - Here's What HappenedProtagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.4% - Here's What HappenedNovember 5, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Given Outperform Rating at WedbushWedbush restated an "outperform" rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a report on Monday.November 4, 2024 | marketbeat.comState of Alaska Department of Revenue Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)State of Alaska Department of Revenue purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 33,615 shares of the company's stNovember 3, 2024 | marketbeat.com‘Smile’ Producers Temple Hill Line Up Next Horror Movie In The Shape Of ‘Monitor’; Protagonist Launching For AFMNovember 2, 2024 | msn.com28,500 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Louisiana State Employees Retirement SystemLouisiana State Employees Retirement System acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 28,500 shares of the company's stock, valuedNovember 2, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by BrokeragesProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has been given an average rating of "Buy" by the six analysts that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a sNovember 1, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Allspring Global Investments Holdings LLC lifted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 24,162.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,842 shares of the company'October 29, 2024 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High - Here's What HappenedProtagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Here's WhyOctober 28, 2024 | marketbeat.comCavalier Investments LLC Buys Shares of 29,956 Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Cavalier Investments LLC purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 29,956 shares of the company's stock, valued at approxOctober 28, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Short Interest Down 14.8% in OctoberProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) was the recipient of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 3,000,000 shares, a drop of 14.8% from the September 30th total of 3,520,000 shares. Based on an average daily volume of 656,700 shares, the days-to-cover ratio is presently 4.6 days.October 28, 2024 | marketbeat.comMoody Aldrich Partners LLC Has $5.37 Million Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Moody Aldrich Partners LLC lessened its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 11.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 119,287 shares of the company's stock after selling 14,928 shares durOctober 24, 2024 | marketbeat.comProtagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune DiseasesOctober 19, 2024 | finance.yahoo.comSwedbank AB Buys New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Swedbank AB purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 50,000 shares of the company's stock, valued at approximatelOctober 19, 2024 | marketbeat.comThe Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is PriceyOctober 16, 2024 | seekingalpha.comState Street Corp's Strategic Acquisition in Protagonist Therapeutics IncOctober 16, 2024 | finance.yahoo.comProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High - Still a Buy?Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week High - Time to Buy?October 15, 2024 | marketbeat.comTD Cowen Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)October 15, 2024 | markets.businessinsider.comInspire Investing LLC Acquires 26,280 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Inspire Investing LLC increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 256.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,514 shares of the cOctober 14, 2024 | marketbeat.comAQR Capital Management LLC Sells 55,952 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)AQR Capital Management LLC lowered its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 69.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,055 shares of the company'sOctober 13, 2024 | marketbeat.comCubist Systematic Strategies LLC Has $2.92 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Cubist Systematic Strategies LLC increased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1,304.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 84,202 shares of the company's stock after purchasingOctober 12, 2024 | marketbeat.comSG Americas Securities LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)SG Americas Securities LLC raised its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 135.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,740 shares of the company's stock after buying an adOctober 11, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Has $3.96 Million Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)The Manufacturers Life Insurance Company boosted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 27.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 114,406 shares of the company's sOctober 8, 2024 | marketbeat.comHsbc Holdings PLC Has $257,000 Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Hsbc Holdings PLC lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 93.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,529 shares of the company's stock after selling 105,3October 5, 2024 | marketbeat.comDimensional Fund Advisors LP Sells 175,172 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Dimensional Fund Advisors LP decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 22.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 616,172 shares of the company'sOctober 4, 2024 | marketbeat.comNorthwestern Mutual Wealth Management Co. Acquires New Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Northwestern Mutual Wealth Management Co. acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 157,788 shares of the company's stock, valuedOctober 3, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by American Century Companies Inc.American Century Companies Inc. cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 83.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,311 shares of the company's stock after selling 133,009 shares during the period.October 2, 2024 | marketbeat.comPerceptive Advisors LLC Raises Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Perceptive Advisors LLC increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 27.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,268,735 shares of the company's stoSeptember 30, 2024 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Marshall Wace LLPMarshall Wace LLP cut its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 41.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 572,177 shares of the company's stock after selling 404,7September 28, 2024 | marketbeat.comPoint72 Asset Management L.P. Has $31.52 Million Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Point72 Asset Management L.P. reduced its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 24.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 909,734 shares of the company's stoSeptember 27, 2024 | marketbeat.comDark Forest Capital Management LP Invests $2.11 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Dark Forest Capital Management LP purchased a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 60,962 shares of the company's stock, valuedSeptember 26, 2024 | marketbeat.com Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼0.620.56▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼174▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amphastar Pharmaceuticals News Calliditas Therapeutics AB (publ) News Phibro Animal Health News Esperion Therapeutics News Cara Therapeutics News Revolution Medicines News Qiagen News Intra-Cellular Therapies News Roivant Sciences News Ascendis Pharma A/S News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
